Measurable residual disease in childhood B-cell acute lymphoblastic leukemia.

IF 1.5 Q3 HEMATOLOGY
血液科学(英文) Pub Date : 2022-10-01 Epub Date: 2022-10-10 DOI:10.1097/BS9.0000000000000112
Robert Peter Gale
{"title":"Measurable residual disease in childhood B-cell acute lymphoblastic leukemia.","authors":"Robert Peter Gale","doi":"10.1097/BS9.0000000000000112","DOIUrl":null,"url":null,"abstract":"In a recent report in Nature Cell Biology (2022. 24:242–52) Zhang and coworkers discuss comparative genetic and bio-chemical features of leukemia cells from children with B-cell acute lymphoblastic leukemia (ALL) obtained at diagnosis, in remission, and at relapse. 1 The authors analyzed large numbers of single-cell transcriptomes looking for dynamic changes and simultaneously, B-cell receptor sequences. They report that in contrast to leukemia cells at diagnosis, those at relapse shifted to a poorly-differentiated state. Changes in residual leukemia cells in remission were more complicated. Differential functional analyses highlighted activation of the hypoxia pathway in residual leukemia cells which correlated with drug resistance which was reversible with appropriate drug interventions in in vitro and in vivo models. The authors suggest this might be a therapy approach to eradicating measurable residual disease (MRD) in childhood B-cell ALL. This is a data dense article which requires understanding a machine learning algorithm. I suggest putting aside at least 5 hours to read and understand the text and supplement. I had to read it twice. This is not something to breeze through while texting on WeChat if you really want to understand the authors’ message and to critique it appropriately. First, a word on nomenclature. The authors use the term minimal residual disease . As John Goldman and I discussed several years ago the correct term is measurable residual disease . 2 Minimal is a subjective term; minimal to 1 person is not necessarily minimal to another. What we are considering is what can and cannot be measured in someone in complete histological remis- sion. (Another source of confusion; remissions are histological , not morphological . Morphology comes from the Greek μ&z. omicr; ρϕ which means form, structure or shape, not appear-ance). As an aside Morpheus was the Greek God of sleep and is the root of the drug name morphine. Lest you think I’m getting lost in semantics please recall the comment from George Orwell:","PeriodicalId":67343,"journal":{"name":"血液科学(英文)","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9595042/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"血液科学(英文)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/BS9.0000000000000112","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/10/10 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

In a recent report in Nature Cell Biology (2022. 24:242–52) Zhang and coworkers discuss comparative genetic and bio-chemical features of leukemia cells from children with B-cell acute lymphoblastic leukemia (ALL) obtained at diagnosis, in remission, and at relapse. 1 The authors analyzed large numbers of single-cell transcriptomes looking for dynamic changes and simultaneously, B-cell receptor sequences. They report that in contrast to leukemia cells at diagnosis, those at relapse shifted to a poorly-differentiated state. Changes in residual leukemia cells in remission were more complicated. Differential functional analyses highlighted activation of the hypoxia pathway in residual leukemia cells which correlated with drug resistance which was reversible with appropriate drug interventions in in vitro and in vivo models. The authors suggest this might be a therapy approach to eradicating measurable residual disease (MRD) in childhood B-cell ALL. This is a data dense article which requires understanding a machine learning algorithm. I suggest putting aside at least 5 hours to read and understand the text and supplement. I had to read it twice. This is not something to breeze through while texting on WeChat if you really want to understand the authors’ message and to critique it appropriately. First, a word on nomenclature. The authors use the term minimal residual disease . As John Goldman and I discussed several years ago the correct term is measurable residual disease . 2 Minimal is a subjective term; minimal to 1 person is not necessarily minimal to another. What we are considering is what can and cannot be measured in someone in complete histological remis- sion. (Another source of confusion; remissions are histological , not morphological . Morphology comes from the Greek μ&z. omicr; ρϕ which means form, structure or shape, not appear-ance). As an aside Morpheus was the Greek God of sleep and is the root of the drug name morphine. Lest you think I’m getting lost in semantics please recall the comment from George Orwell:
儿童b细胞急性淋巴细胞白血病可测量的残留病。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.70
自引率
0.00%
发文量
0
审稿时长
10 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信